StockNews.com downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a strong-buy rating to a buy rating in a report published on Wednesday. A number of other research analysts have also recently commented on ALNY. William Blair restated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, January 8th. […]
Royal Bank of Canada reissued their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $235.00 target price on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Wells Fargo & […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They currently have a $200.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 33.49% from […]
Liontrust Investment Partners LLP Lowers Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Swiss National Bank lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 10.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 400,600 shares of the biopharmaceutical company’s stock after selling 47,000 shares during the quarter. Swiss National Bank’s holdings […]